Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Palbociclib-Fulvestrant'

Palbociclib-Fulvestrant published presentations and documents on DocSlides.

Module 8: ER-Positive Metastatic
Module 8: ER-Positive Metastatic
by anastasia
Breast Cancer . Elizabeth O’Reilly, MSN, MPH, AN...
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
by felicity
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
Fulvestrant 500 mg versus
Fulvestrant 500 mg versus
by elena
anastrozole. as first-line treatment for advanced...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Supplementary Material and Figures
Supplementary Material and Figures
by SoulfulDreamer
Analysis . of the CDK4/6 Cell-Cycle Pathway in Lei...
CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data
CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data
by min-jolicoeur
CDK 4/6 Inhibitors in Breast Cance...
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer
by min-jolicoeur
This program will include a discussion of off-lab...
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
by byrne
Overall survival and updated progression-free surv...
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
by leah
Mansoor A Khan, BS, MS, BCOP. Oncology/Hematology/...
Endocrine resistance: molecular pathways and rational development of targeted therapies
Endocrine resistance: molecular pathways and rational development of targeted therapies
by spottletoefacebook
Grazia Arpino. Università di Napoli Federico II. ...
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo
by tawny-fly
Post-Menopausal Women with Hormone-Receptor Posit...
Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications
Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications
by calandra-battersby
An Interactive Oncology Grand Rounds Series. Joyc...
Hormone Receptor Positive Metastatic Breast Cancer
Hormone Receptor Positive Metastatic Breast Cancer
by pamella-moone
. 5/9/2017. The Lancet July 11, 1895. ON THE TRE...
Targeting endocrine-resistance pathways in breast cancer
Targeting endocrine-resistance pathways in breast cancer
by alexa-scheidler
Targeting endocrine-resistance pathways in breas...
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
by min-jolicoeur
HR Advanced Breast Cancer. Introduction. Restagi...
Hormone Receptor-Positive Advanced Breast Cancer:
Hormone Receptor-Positive Advanced Breast Cancer:
by min-jolicoeur
HR Advanced Breast Cancer:. Introduction. Case S...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...